DE60116075D1 - Behandlung von tumoren mit photodynamischer therapie - Google Patents

Behandlung von tumoren mit photodynamischer therapie

Info

Publication number
DE60116075D1
DE60116075D1 DE60116075T DE60116075T DE60116075D1 DE 60116075 D1 DE60116075 D1 DE 60116075D1 DE 60116075 T DE60116075 T DE 60116075T DE 60116075 T DE60116075 T DE 60116075T DE 60116075 D1 DE60116075 D1 DE 60116075D1
Authority
DE
Germany
Prior art keywords
photodynamic therapy
tumors
treatment
tumor
bearing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60116075T
Other languages
English (en)
Other versions
DE60116075T2 (de
DE60116075T4 (de
Inventor
C Fanslow
K Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DE60116075D1 publication Critical patent/DE60116075D1/de
Publication of DE60116075T2 publication Critical patent/DE60116075T2/de
Application granted granted Critical
Publication of DE60116075T4 publication Critical patent/DE60116075T4/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE60116075T 2000-04-25 2001-04-25 Behandlung von tumoren mit photodynamischer therapie Expired - Fee Related DE60116075T4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19954500P 2000-04-25 2000-04-25
US199545P 2000-04-25
PCT/US2001/013616 WO2001080888A2 (en) 2000-04-25 2001-04-25 Method for treatment of tumors using photodynamic therapy

Publications (3)

Publication Number Publication Date
DE60116075D1 true DE60116075D1 (de) 2006-01-26
DE60116075T2 DE60116075T2 (de) 2006-08-31
DE60116075T4 DE60116075T4 (de) 2007-06-06

Family

ID=22737985

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60116075T Expired - Fee Related DE60116075T4 (de) 2000-04-25 2001-04-25 Behandlung von tumoren mit photodynamischer therapie

Country Status (10)

Country Link
US (2) US20020041864A1 (de)
EP (1) EP1276501B9 (de)
AT (1) ATE313334T1 (de)
AU (2) AU5574001A (de)
CA (1) CA2407336A1 (de)
DE (1) DE60116075T4 (de)
DK (1) DK1276501T5 (de)
ES (1) ES2254408T4 (de)
PT (1) PT1276501E (de)
WO (1) WO2001080888A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60220642T2 (de) * 2001-01-30 2008-02-21 Altachem Pharma Ltd. Perylenequinone zur anwendung mit immunotherapeutischen mitteln
ES2364816T3 (es) * 2001-04-02 2011-09-14 Genentech, Inc. Terapia de combinación.
WO2003094767A1 (en) * 2002-03-25 2003-11-20 The General Hospital Corporation Methods of adjuvant photodynamic therapy to enhance radiation sensitization
US8372409B2 (en) * 2003-04-09 2013-02-12 University Of Florida Research Foundation, Inc. Dendritic cell binding proteins and uses thereof
CA2615510A1 (en) * 2005-08-10 2007-02-15 Quest Pharmatech Inc. Perylenequinone derivatives and uses thereof
US8454991B2 (en) * 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
US20100255080A1 (en) * 2009-04-02 2010-10-07 Sesvalia Usa, Llc Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
EP2718457A4 (de) * 2011-06-06 2014-12-24 Immungene Inc Manipulierte ligandenfusionsmoleküle mit einem antikörper-tnfsf-element
WO2020047327A2 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Flt3l-based chimeric proteins
EP3982981A4 (de) * 2019-06-17 2023-07-19 Enochian Biopharma, Inc. Auf allogenen t-zellen basierter hiv-impfstoff zur induktion von zellulärer und humoraler immunität
TW202305125A (zh) 2021-04-30 2023-02-01 美商凱立凡爾免疫治療股份有限公司 用於經修飾mhc表現之溶瘤病毒
AU2022292632A1 (en) * 2021-06-17 2023-12-21 Kalivir Immunotherapeutics, Inc. Tnfsf-l fusion proteins and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
ES2252732T3 (es) * 1992-05-26 2006-05-16 Immunex Corporation Nueva citoquina que une cd30.
DE69433820T2 (de) * 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
US6495129B1 (en) * 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
SI9620116A (sl) * 1995-10-04 1999-08-31 Immunex Corporation Stimulatorni faktor dendritičnih celic
US6146409A (en) * 1996-05-20 2000-11-14 Bergein F. Overholt Therapeutic methods and devices for irradiating columnar environments
IL127912A0 (en) * 1996-07-10 1999-11-30 Immunex Corp Method of activating dendritic cells
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
WO2000051638A1 (en) * 1999-02-26 2000-09-08 Qlt Phototherapeutics Inc. Photodynamic therapy in combination with apoptosis inducing factors
US6756141B2 (en) * 2001-04-17 2004-06-29 Southwest Research Institute Three-electrode fuel cell

Also Published As

Publication number Publication date
ATE313334T1 (de) 2006-01-15
ES2254408T4 (es) 2007-10-01
US20020041864A1 (en) 2002-04-11
ES2254408T3 (es) 2006-06-16
DK1276501T5 (da) 2007-02-26
PT1276501E (pt) 2006-05-31
DK1276501T3 (da) 2006-04-24
US20050129689A1 (en) 2005-06-16
DE60116075T2 (de) 2006-08-31
EP1276501B9 (de) 2007-01-24
EP1276501A2 (de) 2003-01-22
WO2001080888A3 (en) 2002-08-29
EP1276501B1 (de) 2005-12-21
AU5574001A (en) 2001-11-07
DE60116075T4 (de) 2007-06-06
WO2001080888A2 (en) 2001-11-01
CA2407336A1 (en) 2001-11-01
AU2001255740B2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
NO993393D0 (no) Fotokjemoterapeutiske blandinger
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
DE60116075D1 (de) Behandlung von tumoren mit photodynamischer therapie
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
ATE406897T1 (de) Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
TW200724158A (en) Combination therapy in the treatment of cancer
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
WO2000006136A3 (en) Therapeutic combination of polyamine with an anticancer agent
DE60120917D1 (de) Kombinationspräparat zur krebstherapie
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
ATE354373T1 (de) Verabreichung von gammaglobulinen zur behandlung von lymphomen
RU97114158A (ru) Способ лечения злокачественных опухолей
RU94024337A (ru) Антиметастатическое средство
RU94021014A (ru) Способ лечения злокачественных опухолей методом фотодинамической терапии
DK0455769T3 (da) Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker
RU2004136304A (ru) Хиноновое терапевтическое средство для лечения заболевания печени
RU99122488A (ru) Способ лечения рака эндометрия
WO2003072737A3 (en) Biological inhibitions induced by contact inhibitory factor
WO2005006947A3 (en) Cells for use in locating and targeting tumor cells
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
RU2001132695A (ru) Способ лечения поздних лучевых повреждений кожи и подкожной клетчатки

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee